Opinion|Videos|August 28, 2024
The Future of AYA ALL
The panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.
Advertisement
Video content above is prompted by the following:
- Discuss the role of clinical trials and innovative therapies in improving outcomes for patients with AYA ALL.
Advertisement
Related to this article
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.
Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
4
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
5